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Phosphorus administration in patients with profound hypophosphate-
mia. The influence of severe hypophosphatemia (l.0 mg/dl) on
vitamin D metabolism was prospectively determined in 11 patients
before and after intravenous phosphorus administration. Evidence of
liver dysfunction was present in ten patients. The mean (± SE) plasma 25
hydroxycholecalciferol [25(OH)D] was significantly decreased before
phosphorus therapy when compared to control subjects (9.4 1.3 vs.
17.8 1.3 nglml, P < 0.001). With phosphorus administration, serum
phosphorus increased from 0.59 0.07 to 2.58 0.09 mg/dl while 1,25
dihydroxycholecalciferol [l,25(OH)2D] decreased from 34.6 4.3 to
14.3 2.9 pglml (P < 0.001). Plasma 25(OH)D, plasma immunoreactive
PTH (both amino and carboxyterminal) and serum calcium did not
change after phosphorus administration, suggesting that phosphorus
alone was responsible for the change in plasma I ,25(OH)2D concentra-
tion. An inverse correlation was found between serum phosphorus and
plasma I ,25(OH)2D (r = —0.62, P < 0.005). In addition, a direct
correlation was observed between plasma 25(OH)D and I ,25(OH)2D
both before (r = 0.66, P < 0.005) and after (r = 0.74, P < 0.005)
phosphorus administration. Thus, the decrease in I ,25(OH)2D levels
with phosphorus therapy suggests a role of serum phosphate in the
regulation of this sterol, and hypophosphatemia or phosphorus deple-
tion may change the relationship of substrate [25(OH)D] to product
[I ,25(OH)2D].
Administration de phosphore chez des malades atteints d'hypophospha-
témie profonde. L'influence d'une hypophosphatemie sévère ( 1,0
mg/dl) sur le métabolisme de Ia vitamine D a été déterminé prospective-
ment chez onze malades avant et après administration intraveineuse de
phosphore. L'existence d'un dysfonctionnement hépatique était prouvé
chez dix malades. Le 25 hydroxycholécalciférol plasmatique moyen
(±sE) [25(OH)DI était significativement diminué avant le traitement par
le phosphore, par rapport aux sujets contrôles (9,4 1,3 contre 17,8
1,3 nglml, P < 0.001). Lors de l'administration de phosphore, le
phosphore sérique s'est élevé de 0,59 0,7 a 2,58 0,09 mg/dl tandis
que Ic 1,25 dihydroxycholécalciférol [I ,25(OH)2D] s'abaissait de 34,6
4,3 a 14,3 2,9 pg/mI (P < 0.001). Le 25(OH)D plasmatique, PTH
plasmatique immunoréactive (amino et carboxyterminaux) et Ic calcium
serique ne se sont pas modifies apres administration de phosphore, cc
qui suggere que le phosphore seul était responsable de Ia modification
de La concentration de I ,25(OH)2D plasmatique. Une correlation in-
verse a éte trouvée entre Ic phosphore serique et le I ,25(OH)2D
plasmatique (r = —0,62, P < 0.005). En outre, une correlation directe a
été observée entre le 25(OH)D et le I ,25(OH)2D plasmatiques avant (r =
0,66, P < 0.005) comme aprés (r = 0,74, P < 0.005) administration de
phosphore. Ainsi, Ia diminution des niveaux de 1 ,25(OH)2D lors de Ia
phosphothérapie suggére un role du phosphate serique dans Ia régula-
tion de cc stérol, et l'hypophosphatemie ou Ia déplétion phosphorée
pourraient modifier Ia relation entre Ic substrat [25(OH)D] a Ic produit
[I ,25(OH)2D1.
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Phosphorus depletion and hypophosphatemia are associated
with alterations in vitamin D metabolism [1—5]. The elevated
1,25 dihydroxycholecalciferol [1 ,25(OH)2D] levels found in
phosphorus depletion do not appear to be influenced by PTH [2,
51. In normal human volunteers with dietary-induced hypophos-
phatemia, elevations in 1 ,25(OH)2D were observed only in the
female population [4]. Although a direct effect of phosphorus on
renal 1-alpha hydroxylase has been postulated [1—3], the precise
mechanism by which phosphorus controls production of
l,25(OH)2D has not been identified to our knowledge.
In the present study, we evaluated the effects of phosphorus
repletion on plasma levels of 1 ,25(OH)2D, 25 hydroxycholecal-
ciferol 25(OH)D, and immunoreactive PTH in patients with
profound hypophosphatemia. An inverse relationship between
plasma 1 ,25(OH)2D and serum phosphorus concentration was
observed, and a direct correlation between plasma levels of
25(OH)D and 1 ,25(OH)2D was found before and after phospho-
rus administration. In addition, this correlation between
1 ,25(OH)2D and phosphorus was not PTH-dependent and was
not associated with changes in levels of 25(OH)D.
Methods
Eleven patients (eight males and three females) with severe
hypophosphatemia (serum phosphorus 1.0 mg/dI) were stud-
ied prospectively during the winter season. Criteria for entering
the study included severe hypophosphatemia plus normal se-
rum urea nitrogen and creatinine; urine output was greater than
30 cclhr; and there was an absence of hyperkalemia. Severe
hypophosphatemia developed in the patients ito 6 days follow-
ing hospital admission. Each patient received intravenous phos-
phorus by continuous infusion at a starting dose of 0.32
mmoles/kg of body wt per 12 hr. The infusion vehicle was
0.45% saline. Phosphorus therapy was continued until the
serum phosphorus reached 2.0 mgldl or greater. In two patients,
a higher dose of phosphorus (0.48 mmoles/kg of body wt per 12
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Table 1. Characteristics of hypophosphatemic patients prior to treatment
Serum glutamic Serum
Serum Serum Serum oxaloacetic total
Presumed etiologies phosphorus calcium albumin transaminase bilirubin
Patient no, Age Sex of hypophosphatemia mg/dl mg/dl gld! lU/liter mg/dl
1 47 M Ethanol 0.6 9.9 4.2 151 2.5
2 56 M Malabsorption,
hyperalimentation
0.5 7.4 1.7 120 1.7
3 59 F Antacids 0.7 7.8 3.2 135 1.2
4 26 F Hepatitis 0.3 7.8 2.8 1212 7.5
5 54 M Ethanol 0.6 7.2 2.6 335 2.0
6 55 M Ethanol 1.0 7.0 3.1 251 1.6
7 70 M Cancer,
hyperalimentation
0.5 8.4 2.4 70 3.3
8 63 F Cancer,
hyperalimentation
0.8 8.7 3.9 285 10.0
9 55 M Ethanol, diabetes 0.9 8.0 3.5 96 4.9
10 53 M Cancer, ethanol 0.5 7.4 2.0 41 1.3
11 52 M Ethanol 0.2 7.9 2.8 177 4.3
Normal range 2.5 to 4.5 8.5 to 10.5 3.5 to 5.0 0 to 40 0.2 to 1.2
hr) was instituted after 6 hr because the initial dose failed to
substantially raise the serum phosphorus. Diets were adjusted
according to the clinical condition and ability to ingest food by
mouth. Intravenous fluids were administered as clinically indi-
cated to correct volume depletion and no glucose solutions
were given. Consent forms were obtained from each patient as
required by the Institutional Review Board of the University of
Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Blood and urine samples were collected immediately before
and 6 hr after beginning the phosphorus infusion and every 12 hr
thereafter until the serum phosphorus reached 2.0 mg/dl. Speci-
mens were processed immediately after retrieval or stored at
—30°C until analyzed. Serum and urinary calcium, phosphorus,
creatinine, serum albumin, serum glutamic oxaloacetic trans-
aminase, and serum glutamic pyruvic transaminase determina-
tions were made with a multichannel Technicon AutoAnalyzer.
Serum magnesium was determined by the standard colorimetric
technique. Plasma immunoreactive PTH, measured both by
amino and carboxyterminal radioimmunoassay, was deter-
mined in our laboratory according to a previously described
method [6]. Normal plasma levels were 0.05 to 0.5 nglml for the
carboxyterminal fragment and 0.05 to 0.4 ng/ml for the amino-
terminal fragment. Interassay coefficient of variation was be-
tween 10 and 12%. Measurements of 1,25(OH)2D were per-
formed in triplicate by radioreceptor assay as described else-
where [7]. The assay for 25(OH)D was performed by a method
recently described which involves an improved competitive
protein binding assay [8]. The normal l,25(OH)2D and 25(OH)D
plasma levels range from 20 to 50 pg/ml and 8 to 46 ng/ml,
respectively. The mean plasma 25(OH)D value in 19 control
subjects from Oklahoma City determined during winter was
17.8 1.3 ng/ml (range, 8 to 28 ng/ml). The above-mentioned
normal levels of vitamin D are data from Dokoh, Liach, and
Haussler [81 in control subjects from Arizona determined during
September. Interassay coefficient of variation was 10 to 15%.
Urinary cyclic AMP was determined by competitive binding
assay.
Statistical analysis was performed with the Student t test and
linear regression analysis. All results are expressed as the mean
value SE.
Results
The clinical profile of all hypophosphatemic patients prior to
phosphorus treatment is shown in Table 1. Etiologies of hypo-
phosphatemia were multiple and included alcohol abuse (six
patients), phosphorus binding antacids (two patients), hyperali-
mentation (three patients), and diabetes (one patient). In addi-
tion, seven patients denied any food ingestion for at least 48 hr
prior to admission. At the time of the study, the serum
phosphorus ranged from 0.2 to 1.0 mg/dl. Liver enzymes were
elevated in ten patients and the serum albumin level was
decreased in eight. All patients had normal serum creatinine
and urea nitrogen on admission; these parameters remained
normal throughout the study. The serum phosphorus concen-
tration increased in all 11 patients to 2.0 mg/dl or greater within
48 hr of starting the phosphorus infusion. Four patients attained
this level by 36 hr and five patients within 24 hr.
Biochemical data for all patients before and at the completion
of phosphorus therapy are displayed in Table 2. The mean
baseline value for serum phosphorus was 0.59 0.07 mg/dl.
After correction of hypoalbuminemia (reduction of 0.8 mg/dl for
each gram per deciliter reduction in serum albumin), the
baseline serum calcium level was within the normal range in all
except patient number 6. The mean baseline values for plasma
PTH, carboxyterminal, was 0.43 0.09 ng/ml; aminoterminal
was 0.19 0.05 ng/ml; and serum magnesium was 1.58 0.15
mEq/liter. All these values were within the normal range. The
mean baseline plasma 25(OH)D prior to phosphorus therapy as
compared with normal values decreased significantly (9.4 1.3
vs. 17.8 1.3 ng/ml;P< 0.001). After phosphorus therapy, the
mean serum phosphorus level increased to 2.58 0.09 mg/dl.
No significant changes occurred in serum levels of calcium and
magnesium, or plasma levels of PTH (carboxy and aminoter-
minal) and 25(OH)D. No patient developed acidosis during the
study.
Baseline 1,25(OH)2D concentrations were elevated in two
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Determination
Baseline(N = 11)
After
(N = 11)
Serum
Phosphorus (2.5 to 4.5 mg/dl) 0.59 0.07 2.58 0.09b
Calcium (8.5 to 10.5 mg/dl) 7.95 0.20 8.05 0.34
Magnesium (1.4 to 1.9 mEq/liter) 1.58 0.15 1.46 0.12
Plasma
PTH
(C:0,05 to 0.5 nglml) C-0.43 0.09 C-0.41 0.10
(N:0.05 to 0.4 ng/ml) N-0.19 0.05 N-0.15 0.04
25(OH)D (8 to 46 ng/ml) 9.4 1.3 10.6 1.8
1,25(OH)2D (20 to 50 pg/mI) 34.6 4.3 14.3 2.9k'
patients (one male and one female), normal in seven, and below
normal in two. As displayed in Figure 1, the 1,25(OH)2D
concentration decreased during phosphorus infusion in all pa-
tients; in nine the postinfusion l,25(OH)2D levels were below
normal. The mean plasma l,25(OH)2D level decreased with
phosphorus therapy from 34.6 4.3 to 14.3 2.9 pg/mi (P <
0.001). As shown in Figure 2, an inverse correlation was found
between the level of serum phosphorus and 1 ,25(OH)2D (P <
0.005). There was no correlation between plasma PTH (carboxy
and aminoterminal) and 1 ,25(OH)2D. However, a direct correla-
tion was observed between the levels of 25(OH)D and
1 ,25(OH)2D (Fig. 3), both before and after phosphorus therapy
(P < 0.005).
Presented in Table 3 are the urinary data before and after
phosphorus infusion. The renal excretion of phosphorus in-
creased with phosphorus administration from 2.6 1.3 to 16.4
5.4 mg/hr (P < 0.02) while the tubular reabsorption of
phosphorus was unchanged from baseline (86 7 vs. 86 6%).
The tubular reabsorption of phosphorus corrected for glomeru-
lar filtration rate (TRP/GFR) increased significantly following
phosphorus repletion (0.77 0.13 vs. 2.84 0.39 mg/dl, P <
0.001). No significant changes were observed in urinary calcium
(5.39 1.54 vs. 3.29 0.97 mg/hr) or urinary cyclic AMP (4.76
0.53 vs. 8.05 2.71 moles/g of creatinine) following
treatment with phosphorus.
Discussion
The results of our study confirm previous findings in humans,
demonstrating an inverse correlation between serum phospho-
rus and plasma l,25(OH)2D concentrations [4]. In addition, this
relationship was present in males as well as females, and PTH
did not appear to play a regulatory role. Similar results have
been obtained in the rat [1, 9]. As opposed to the aforemen-
tioned studies in which hypophosphatemia was produced by a
phosphorus-restricted diet, the patients in the present study
presented with severe hypophosphatemia as a consequence of
naturally occurring clinical conditions. In addition, severe
hypophosphatemia was the basal state, as contrasted with
dietary induced hypophosphatemia. Furthermore, since all of
our patients had liver disease or additional anomalies, any
Serum phosphorus, mg dl
Fig. 1. Relationship of plasma 1,25(OH)2D to serum phosphorus before
(0) and after (•) phosphorus infusion.
extrapolation of the present results with the normal state may
not be justified.
In contrast to the findings in which plasma l,25(OH)2D levels
become elevated during phosphorus deprivation in healthy
women [4], plasma 1 ,25(OH)2D levels in the present study were
inappropriately low for the hypophosphatemia. One possible
explanation for this difference concerns vitamin D binding
protein. Three previous studies have shown that vitamin D
binding protein levels are depressed in states of hypoproteine-
mia and cirrhosis [10—121. Vitamin D binding protein is presum-
ably a carrier protein and thus, physiologic responses depend
on free hormone levels [13]. Free levels of l,25(OH)2D can be
determined, according to the law of mass action by the ratio of
total vitamin D metabolite to vitamin D binding protein [14].
Thus, although both total 1 ,25(OH)2D and vitamin D binding
protein may be depressed, the free level of 1 ,25(OH)2D may be
normal or elevated if vitamin D binding protein is decreased
more than total 1 ,25(OH)2D. Such a situation has been reported
in the cord serum of full-term neonates [15]. Therefore, since
vitamin D binding protein was probably decreased in our
patients, total l,25(OH)2D levels may not reflect the free levels
of l,25(OH)2D; it is possible that during hypophosphatemia the
free levels of l,25(OH)2D may have been elevated.
Another possibility is that the levels of total 1 ,25(OH)D may
accurately reflect free levels of I ,25(OH)2D and were normal
during hypophosphatemia. An enterohepatic circulation for
1,25(OH)2D has been reported in normal males [16]. Thus,
malabsorption of l,25(OH)2D may occur with hepatic disease.
Our failure to observe elevated concentrations of 1 ,25(OH)2D
may be secondary to malabsorption [17].
The presence of liver dysfunction in ten patients may be
significant since previous studies have shown decreased serum
25(OH)D levels in patients with hepatic disease [18—22]. A
defect in 25 hydroxylase activity has been postulated as an
etiology for the low sterol levels [19, 20], but inadequate dietary
intake, insufficient sunlight exposure and malabsorption are
additional important etiologic factors [2 1—23]. In noncirrhotic
patients with alcoholic liver disease, low serum 25(OH)D levels
Table 2. Biochemical data before and after correction of 50
40
0.
30I0
Lfl
20
Cs
E
0,
Cs
10
a Mean SEM; normal ranges are in parentheses.b P < 0.001.
0.5 1.0 1.5 2.0 2.5 3.0 3.5
554 Andress et a!
th
I0
U)N
cn
E0)
a-
returned to normal following treatment with oral vitamin D [21—
23], However, some cirrhotic patients failed to increase
25(OH)D concentrations after vitamin D [19], suggesting that
the severity of hepatic dysfunction is important in the control of
25 hydroxylase activity.
A direct correlation was observed between plasma 25(OH)D
and 1 ,25(OH)2D both before and after correction of hypophos-
phatemia. As shown in Fig. 3, plasma l,25(OH)2D levels
decreased after therapy with phosphorus and yet maintained a
positive correlation with a lesser slope. Whether a direct
relationship between 25(OH)D and l,25(OH)2D exists is not
clear. Caldas, Gray, and Lemann [24] were unable to find a
direct relationship between 25(OH)D and 1 ,25(OH)2D in normal
individuals or calcium stone formers. Gray et al [41 found no
direct relationship between 25(OH)D and 1 ,25(OH)2D during
phosphate depletion in healthy subjects, calcium stone formers,
or patients with primary hyperparathyroidism. However, ad-
ministration of 40 pg/day of 25(OH)D for 7 days produced
increases in both 25(OH)D and 1 ,25(OH)2D in normal adult
males, male calcium stone formers, elderly female osteoporo-
tics, and vitamin D deficient osteomalacic patients [25]. Admin-
istration of 2.5 mg/day of vitamin D for 4 days elevated
l,25(OH)2D levels in normal children but not normal adults [26].
In both hypoparathyroidism and in children with GFR less than
25 ml/min!l.73 m2 a positive correlation was found between
25(OH)D and 1 ,25(OH)2D [27, 28]. In patients receiving mainte-
nance hemodialysis, the administration of vitamin D3 is capable
of increasing l,25(OH)2D concentrations [29]. Seasonal fluctua-
tions in I ,25(OH)2D levels that correlate with changes in
25(OH)D have been shown by some investigators [30, 31], but
not others [32, 331. In vitamin D deficiency, levels of 25(OH)D
are low and I ,25(OH)2D levels are generally low or low normal
[34—36]. Therapy with either vitamin D or 25(OH)D results in
rapid increases in l,25(OH)2D to supranormal levels [34—36].
However, in states of vitamin D deficiency, secondary hyper-
parathyroidism is usually present and thus PTH may participate
in the augmented 1,25(OH)2D production. Thus, although a
0I0
LnN
E(0
0
Plasma 25(OH)D, ng/mI
Fig. 3. Relationship of plasma I ,25(OH)2D to plasma 25(OH)D before
(0) and after (•) phosphorus infusion. The baseline is represented by y
= 2.2x + 13.7; after phosphorus therapy, y = 1.2x + 1.5.
direct correlation between 25(OH)D and 1,25(OH)2D was ob-
served in the present study, it is difficult to be certain of a cause
and effect relationship.
Another finding suggested by Figure 3 is that phosphorus
administration may have changed the relationship of substrate
[25(OH)D] to product [1,25(OH)D]. During hypophosphatemia
levels of 1 ,25(OH)2D (product) were higher for the same con-
centration of 25(OH)D (substrate) than after phosphorus admin-
istration which occurred without any concomitant changes in
serum calcium, serum magnesium, or plasma PTH.
All of the patients included in the study had severe hypophos-
phatemia ( 1 mg/dl). In general, hypophosphatemia does not
necessarily indicate phosphorus depletion [37] since intracellu-
lar shifts of phosphorus occur with starvation [37, 38]. There
exists a normal diurnal variation in serum phosphorus levels
and a mean postcibal fall of 0.25 mg/dl below fasting levels [39].
The patients in our study presented with clinical conditions,
such as alcoholism, antacid ingestion, and diabetes, which are
frequently associated with phosphorus depletion. Although
intracellular phosphorus content was not measured, a mean
basal serum phosphorus concentration of 0.59 0.07 mgldl
suggests that in addition to intracellular shifts of phosphorus,
phosphorus depletion may have been present.
Another finding was the presence of impaired tubular reab-
sorption of phosphorus. Most of the patients included in our
study exhibited conditions such as alcoholism and diabetes
which are associated with inappropriate phosphaturia [37, 38].
Mild hypomagnesemia may have been a factor in some patients
[37]. Previous studies of dietary phosphorus restriction or
prolonged antacid administration in animals and humans have
demonstrated marked conservation of urinary phosphorus [40—
45]. During phosphorus deprivation subjects achieved maxi-
r = —0.62
P> 0.005
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Fig. 2. An inverse correlation is observed between the levels of plasma
l,25(OH)2D and serum phosphorus.
.
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Table 3. Urinary data before and after correction of
hypophosphatemia
Determination
Baseline
(N = 11)
After
(N = 11) P value
Urine
Phosphate, mg/hr 2.6 1.3 16.4 5.4 <0.02
Tubular reabsorption
of phosphorus, % 86 7 86 6 NS
TRP/GFR, mg/dl 0.8 0.1 2.8 0.4 <0.001
Calcium, mg/hr 5.4 1.5 3.3 1.0 NS
Cyclic AMP
p.mo/es/g creatinine 4.8 0.5 8.1 2.7 NS
mum renal phosphorus conservation, and this remained con-
stant despite changes in PTH levels [45]. In the present study,
PTH levels remained unchanged. The normal urinary cyclic
AMP values observed throughout the study probably reflect the
absence of change in PTH secretion. Thus, the inappropriate
phosphaturia observed in these patients may not be related to
PTH and may be multifactorial as a direct consequence of their
complex underlying conditions. This observation should be the
subject of a detailed additional study.
In summary, the present study in hypophosphatemic patients
shows an inverse correlation between serum phosphorus and
plasma l,25(OH)2D, and a decrease in the levels of 1,25(OH)2D
with phosphorus administration in all patients. These findings
suggest a possible regulatory role of phosphorus in 1 ,25(OH)2D
production. Furthermore, a correlation existed between
25(OH)D and 1 ,25(OH)2D both before and after phosphorus
administration. However, these findings do not necessarily
establish a cause/effect relationship between these two sterols.
All these changes occurred in the absence of significant changes
in serum calcium, serum magnesium, and plasma PTH.
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